AMAG Pharmaceuticals, Inc. to Host Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2009

LEXINGTON, Mass., Feb 22, 2010 (BUSINESS WIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report
unaudited consolidated financial results for the fourth quarter and year
ended December 31, 2009 before the U.S. financial markets open on March
1, 2010. The announcement will be followed by a conference call and
webcast with slides at 8:00 a.m. ET during which management will discuss
the Company’s financial results, business highlights, commercial
progress and development programs.

To access the conference call via telephone, please dial (877) 412-6083
from the United States or (702) 495-1202 for international access. A
telephone replay will be available from approximately 11:00 a.m. ET on
March 1, 2010 through midnight March 3, 2010. To access a replay of the
conference call, dial (800) 642-1687 from the United States or (706)
645-9291 for international access. The passcode for the live call and
the replay is 54914959.

The call will be webcast with slides and accessible through the
Investors section of the Company’s website at
The webcast replay will be available from approximately 11:00 a.m. ET on
March 1, 2010 through midnight April 1, 2010.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes
its proprietary technology for the development and commercialization of
a therapeutic iron compound to treat iron deficiency anemia and novel
imaging agents to aid in the diagnosis of cancer and cardiovascular
disease. On June 30, 2009, AMAG received approval from the U.S. Food and
Drug Administration to market Feraheme(R) (ferumoxytol)
Injection for intravenous (IV) use for the treatment of iron deficiency
anemia in adult chronic kidney disease patients.

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.

SOURCE: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals
Amy Sullivan, 617-498-3303
Carol Miceli, 617-498-3361